Background: 2019 novel coronavirus disease (COVID-19) has posed significant threats to public health. To identify and treat the severe and critical patients with COVID-19 is the key clinical problem to be solved. The present study aimed to evaluate the clinical characteristics of severe and non-severe patients with COVID-19. Methods:We searched independently studies and retrieved the data that involved the clinical characteristics of severe and non-severe patients with COVID-19 through database searching. Two authors independently retrieved the data from the individual studies, assessed the study quality with Newcastle-Ottawa Scale and analyzed publication bias by Begg's test. We calculated the odds ratio (OR) of groups using fixed or randomeffect models.Results: Five studies with 5,328 patients confirmed with COVID-19 met the inclusion criteria.Severe patents were older and more common in dyspnea, vomiting or diarrhea, creatinine >104 μmol/L, procalcitonin ≥0.05 ng/mL, lymphocyte count <1.5×10 9 /L and bilateral involvement of chest CT. Severe patents had higher risk on complications including acute cardiac injury (OR 13.48; 95% CI, 3.60 to 50.47,

Motoric cognitive risk syndrome (MCR) is a pre-dementia syndrome characterized by subjective cognitive complaints and objective slow gait speed. MCR prevalence varies across different areas and populations: approximately 8.0% in Europe, 7.0% in the United States [1], 6.3% in Japan [2], and 12.8% in China [3]. Many previous studies reported that MCR could lead to a wide range of adverse outcomes, including falls [4], disability [2], increased hospitalization [5], and major neurocognitive disorders [1].

No abstract